Sulfasalazine has been used in the treatment of inflammatory bowel disease for over 60 years. Although the drug is frequently associated with gastrointestinal adverse effects, pulmonary adverse effects are very rare. Herein, we report a case of interstitial fibrosis resulting from 4-month sulfasalazine therapy for ulcerative colitis in a patient under long-term follow-up in our clinic due to chronic obstructive pulmonary disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263240 | PMC |
| http://dx.doi.org/10.5152/eurasianjmed.2018.17302 | DOI Listing |
Publication Analysis
Top Keywords
interstitial fibrosis
8
adverse effects
8
sulfasalazine-induced interstitial
4
fibrosis sulfasalazine
4
sulfasalazine treatment
4
treatment inflammatory
4
inflammatory bowel
4
bowel disease
4
disease years
4
years drug
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!